These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 31468706)

  • 1. Activation of LXRβ inhibits tumor respiration and is synthetically lethal with Bcl-xL inhibition.
    Nguyen TTT; Ishida CT; Shang E; Shu C; Torrini C; Zhang Y; Bianchetti E; Sanchez-Quintero MJ; Kleiner G; Quinzii CM; Westhoff MA; Karpel-Massler G; Canoll P; Siegelin MD
    EMBO Mol Med; 2019 Oct; 11(10):e10769. PubMed ID: 31468706
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dual Inhibition of Bcl-2/Bcl-xL and XPO1 is synthetically lethal in glioblastoma model systems.
    Shang E; Zhang Y; Shu C; Ishida CT; Bianchetti E; Westhoff MA; Karpel-Massler G; Siegelin MD
    Sci Rep; 2018 Oct; 8(1):15383. PubMed ID: 30337641
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LXR agonists promote the proliferation of neural progenitor cells through MEK-ERK pathway.
    Wang JZ; Fang Y; Ji WD; Xu H
    Biochem Biophys Res Commun; 2017 Jan; 483(1):216-222. PubMed ID: 28034754
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of Bcl-2/Bcl-xL and c-MET causes synthetic lethality in model systems of glioblastoma.
    Zhang Y; Ishida CT; Shu C; Kleiner G; Sanchez-Quintero MJ; Bianchetti E; Quinzii CM; Westhoff MA; Karpel-Massler G; Siegelin MD
    Sci Rep; 2018 May; 8(1):7373. PubMed ID: 29743557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activation of LXR Receptors and Inhibition of TRAP1 Causes Synthetic Lethality in Solid Tumors.
    Nguyen TTT; Ishida CT; Shang E; Shu C; Bianchetti E; Karpel-Massler G; Siegelin MD
    Cancers (Basel); 2019 Jun; 11(6):. PubMed ID: 31181660
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BH3-mimetics and BET-inhibitors elicit enhanced lethality in malignant glioma.
    Ishida CT; Bianchetti E; Shu C; Halatsch ME; Westhoff MA; Karpel-Massler G; Siegelin MD
    Oncotarget; 2017 May; 8(18):29558-29573. PubMed ID: 28418907
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Divergent effect of liver X receptor agonists on prostate-specific antigen expression is dependent on androgen receptor in prostate carcinoma cells.
    Tsui KH; Chung LC; Feng TH; Lee TY; Chang PL; Chen WT; Juang HH
    Prostate; 2015 May; 75(6):603-15. PubMed ID: 25560459
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activation of the Liver X Receptor Pathway Inhibits HBV Replication in Primary Human Hepatocytes.
    Zeng J; Wu D; Hu H; Young JAT; Yan Z; Gao L
    Hepatology; 2020 Dec; 72(6):1935-1948. PubMed ID: 32145089
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MET Inhibition Elicits PGC1α-Dependent Metabolic Reprogramming in Glioblastoma.
    Zhang Y; Nguyen TTT; Shang E; Mela A; Humala N; Mahajan A; Zhao J; Shu C; Torrini C; Sanchez-Quintero MJ; Kleiner G; Bianchetti E; Westhoff MA; Quinzii CM; Karpel-Massler G; Bruce JN; Canoll P; Siegelin MD
    Cancer Res; 2020 Jan; 80(1):30-43. PubMed ID: 31694905
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liver X receptor activation inhibits SGLT2-mediated glucose transport in human renal proximal tubular cells.
    Chonlaket P; Wongwan T; Soodvilai S
    Exp Physiol; 2018 Feb; 103(2):250-260. PubMed ID: 29127736
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting the transcription factor receptor LXR to treat clear cell renal cell carcinoma: agonist or inverse agonist?
    Wu G; Wang Q; Xu Y; Li J; Zhang H; Qi G; Xia Q
    Cell Death Dis; 2019 May; 10(6):416. PubMed ID: 31138790
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activation of LXRβ inhibits proliferation, promotes apoptosis, and increases chemosensitivity of gastric cancer cells by upregulating the expression of ATF4.
    Liu J; Qi YB
    J Cell Biochem; 2019 Sep; 120(9):14336-14347. PubMed ID: 31210377
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liver X receptor agonist GW3965 protects against sepsis by promoting myeloid derived suppressor cells apoptosis in mice.
    Zhang W; Luo M; Zhou Y; Hu J; Li C; Liu K; Liu M; Zhu Y; Chen H; Zhang H
    Life Sci; 2021 Jul; 276():119434. PubMed ID: 33785343
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BH3 mimetics potentiate pro-apoptotic activity of encorafenib in BRAF
    Hartman ML; Gajos-Michniewicz A; Talaj JA; Mielczarek-Lewandowska A; Czyz M
    Cancer Lett; 2021 Feb; 499():122-136. PubMed ID: 33259900
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liver × receptor ligands disrupt breast cancer cell proliferation through an E2F-mediated mechanism.
    Nguyen-Vu T; Vedin LL; Liu K; Jonsson P; Lin JZ; Candelaria NR; Candelaria LP; Addanki S; Williams C; Gustafsson JÅ; Steffensen KR; Lin CY
    Breast Cancer Res; 2013 Jun; 15(3):R51. PubMed ID: 23809258
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effects of LXR agonist GW3965 on vascular reactivity and inflammation in hypertensive rat aorta.
    Han S; Bal NB; Sadi G; Usanmaz SE; Uludag MO; Demirel-Yilmaz E
    Life Sci; 2018 Nov; 213():287-293. PubMed ID: 30366037
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BH3-only proteins are dispensable for apoptosis induced by pharmacological inhibition of both MCL-1 and BCL-X
    Greaves G; Milani M; Butterworth M; Carter RJ; Byrne DP; Eyers PA; Luo X; Cohen GM; Varadarajan S
    Cell Death Differ; 2019 Jun; 26(6):1037-1047. PubMed ID: 30185825
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TIC10/ONC201 synergizes with Bcl-2/Bcl-xL inhibition in glioblastoma by suppression of Mcl-1 and its binding partners in vitro and in vivo.
    Karpel-Massler G; Bâ M; Shu C; Halatsch ME; Westhoff MA; Bruce JN; Canoll P; Siegelin MD
    Oncotarget; 2015 Nov; 6(34):36456-71. PubMed ID: 26474387
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An LXR-Cholesterol Axis Creates a Metabolic Co-Dependency for Brain Cancers.
    Villa GR; Hulce JJ; Zanca C; Bi J; Ikegami S; Cahill GL; Gu Y; Lum KM; Masui K; Yang H; Rong X; Hong C; Turner KM; Liu F; Hon GC; Jenkins D; Martini M; Armando AM; Quehenberger O; Cloughesy TF; Furnari FB; Cavenee WK; Tontonoz P; Gahman TC; Shiau AK; Cravatt BF; Mischel PS
    Cancer Cell; 2016 Nov; 30(5):683-693. PubMed ID: 27746144
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liver X receptor activation reduces angiogenesis by impairing lipid raft localization and signaling of vascular endothelial growth factor receptor-2.
    Noghero A; Perino A; Seano G; Saglio E; Lo Sasso G; Veglio F; Primo L; Hirsch E; Bussolino F; Morello F
    Arterioscler Thromb Vasc Biol; 2012 Sep; 32(9):2280-8. PubMed ID: 22723445
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.